Skip to main content
. 2022 Feb 19;45(7):1341–1347. doi: 10.1007/s40618-022-01767-w

Table 2.

Laboratory and imaging features of the patients

TSH fT4 fT3 ESR CRP TgAb TPOAb TRAb Ultrasound and Doppler Findings
1  < 0,005 2,87 8,06 67 53,9 Negative Negative Negative Heterogeneous echotexture, with poorly defined regions of decreased echogenicity and pseudonodules
2 0,015 2,93 6,84 81 193 Negative Negative Negative Ill-defined hypoechoic areas
3 0,01 2,36 5,18 89 88,9 142 Negative Negative Bilateral inflammation and hipovascularity, multiple lymphadenopathy
4  < 0,005 3,74 9,55 72 38,4 Negative Negative Negative Hypoechoic and heterogeneous areas with blurred margins
5 0,01 2,59 4,62 82 78 307 Negative Negative No significant alteration in ultrasonography, reduced 99mTc-perthecnetate uptake
6 0,018 0,942 6,63 79 27  > 4000  > 4000  > 30 Bilateral enlarged thyroid gland, irregularly demarcated hypoechoic areas, decreased vascularity
7  < 0,005 2,04 5,11 89 34 222 Negative Negative Hypoechoic and heterogeneous areas with blurred margins, poorly vascularization
8  < 0,005 3,05 6,59 51 51,8 542 Negative Negative Inflammation and pseudonodularity
9 0,07 4,29 11 33 43,3 Negative Negative Negative Heterogeneous gland with bilateral patchy ill-defined hypoechoic areas
10 0,01 2,32 4,22 83 109 Negative Negative Negative Reduction in gland size, but bilateral inflammation
11 0,024 4,27 9,03 79 125,4 Negative Negative Negative Multiple diffuse hypoechoic areas, decreased vascularity

TSH thyroid stimulating hormone.( 0,27–4,2 uIU/ml) fT4 free thyroxine. (0,93–1,70 ng/dL) fT3 free triiodothyronine. (2,3–4,5 pg/mL) ESR erythrocyte sedimentation rate (0–20 mm/h). C-reactive Protein (0–5 mg/L) TgAb Anti-thyroglobulin antibodies (0–115 IU/mL) TPOAb Thyroid peroxidase antibodies (0–34 IU/mL) TRAb TSH receptor autoantibodies. (0–1,5 U/L)